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Aberrant expression of the transcription factor ERG is a key driving event in approximately
one-half of all of prostate cancers. Lacking an enzymatic pocket and mainly disordered, the
structure of ERG is difficult to exploit for therapeutic design. We recently identified EWS as
a specific interacting partner of ERG that is required for oncogenic function. In this study, we
aimed to target this specific protein-protein interaction with small molecules. A high-through-
put screening (HTS) strategy was implemented to identify potential protein-protein interac-
tion inhibitors. Secondary assays verified the function of several hit compounds, and one
lead compound inhibited ERG-mediated phenotypes in prostate cells. This is the first study
aimed at targeting the ERG-EWS protein-protein interaction for the development of a small
molecule-based prostate cancer therapy.
Introduction
Transcription factors are key modulators of cancer. In many cancers, transcription factor
function is altered through mutation. Additionally, changes in signaling converge on tran-
scription factors which causes cancer-supporting alterations in the transcriptome. Therefore,
understanding how to target transcription factors is essential for advancing the repertoire of
cancer therapies. Traditionally, transcription factors are difficult to specifically inhibit as they
lack hydrophobic enzymatic pockets and often contain intrinsically disordered regions (IDRs)
[1, 2]; however a new area of research aims to exploit other features for inhibition, like specific
protein-protein interactions essential for transcription factor function [3].
The majority of prostate cancer is driven by gene rearrangements that result in the expres-
sion of certain ETS transcription factors that are normally silent in prostate cells [4]. The ETS
transcription factor family is composed of 28 members, some of which are normally expressed
in the prostate and control healthy function [5]. However, rearrangement-induced expression
of the specific ETS factors ERG, ETV1, ETV4, and ETV5 drive an oncogenic gene expression
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program in this ectopic setting [4, 6–8]. ETS factors are classified by the presence of a con-
served ETS DNA binding domain, so targeting the ETS factor-DNA interaction will likely
impact endogenous ETS factors, some of which act as tumor suppressors [6]. Outside of the
structured ETS domain, ETS factors are largely disordered, posing a challenge to rational
structure-based therapeutic design. Therefore, understanding the specific mechanisms that
oncogenic ETS use to drive cancer is essential for the development of precision medicines.
We recently reported that oncogenic ETS factors such as ERG require an interaction with
the RNA binding protein EWS to attain oncogenic function [9]. Expression of a point mutant
of ERG that disrupts the interaction with EWS results in a significant decrease in prostate can-
cer cell migration, clonogenic growth, and anchorage independent growth as well as decreased
tumor formation in mice [9]. This interaction is specific to oncogenic ETS factors—ETS fac-
tors endogenously expressed in the prostate do not interact with EWS. Therefore, the onco-
genic ETS-EWS interaction is a suitable candidate for the development of a specific inhibitor
for clinical use.
In this study, we aimed to develop a strategy to chemically inhibit the oncogenic ETS-EWS
interaction. We specifically chose to target the interaction between ERG and EWS, since ERG is
the most commonly rearranged ETS factor in prostate cancer. Using HTS we identified small
molecule inhibitors of the ETS-EWS interaction. We then performed secondary interaction and
functional assays for hit-to-lead generation. This is the first study aimed at developing inhibitors
of this particular protein-protein interaction. Our results suggest that the ERG-EWS transcrip-
tion factor-coactivator interaction is able to be inhibited by small molecules and the AlphaScreen
(PerkinElmer, Waltham, MA) system is a feasible approach for identifying these inhibitors.
Materials and methods
Construct cloning and protein purification
ERG was purified as previously described [10]. Briefly, ERG was cloned into pET28a (Novagen)
and expressed in BL21 E. coli. ERG was purified with Ni-NTA resin (Qiagen) and eluted using
Imidazole. FLAG-EWS 1-355aa was cloned into pGEX-6p-2-GST-EWS after removal of the full
length EWS gene. EWS 1-355aa was purified as previously described [9]. Briefly, EWS 1-355aa
was expressed in BL21 E. coli, purified using glutathione agarose beads (Pierce), and eluted using
50 mM reduced glutathione. Protein concentration was measured by Bradford assay and by com-
paring band intensity to a standard curve on a coomassie stained SDS-PAGE gel. Protein was
diluted to appropriate working concentrations in assay buffer (1x PBS + 0.5% BSA) before use.
Z’ determination
Assay quality control was performed using 30 nM of both purified proteins, either purified
proteins, or no protein (assay buffer alone), pipetted using a multichannel pipette, into 70
wells of a 384 well plate. Assay plates were then incubated for 1 hr at room temperature. Next,
0.4 μg donor and acceptor resins were added to each appropriate well using a multichannel
pipette. Plates were incubated for 1 hr at room temperature in the dark and read using the
Envision 2102 Multilabel Plate Reader (Perkin Elmer) using the AlphaScreen protocol with
excitation set at 680 nM and emission set at 570 nM. Scatterplots were graphed and Z’ robust
was calculated as previously [11] after the removal of outliers.
AlphaScreen
30 nM of each protein in 10 μl volume was added to plates using MultiFlo FX microplate dis-
pensor (BioTek). Compounds were then stamped from 384 well mother plates to assay plates
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using a Freedom Evo Liquid Handling System (Tecan). Assay plates were then incubated for 1
hr at room temperature. Next, 0.4 μg donor and acceptor resins were added to each appropri-
ate well in 10 μl volume using the MultiFlo FX microplate dispenser and assay plates were
incubated for another 1 hr at room temperature in the dark. Plates were read using the Envi-
sion 2102 Multilabel Plate Reader (PerkinElmer) using the standard AlphaScreen protocol
(PerkinElmer) with excitation set at 680 nM and emission set at 570 nM.
Affinity pull down assay
Roughly 5 μg of purified His-tagged ERG was diluted in 300 μl binding buffer (100mM sodium
phosphate pH 8.0, 600mM NaCl and 0.02% Tween) and incubated with 2.5 μl His-tag isolation
dynabeads (LifeTechnologies) for 1 hr at 4 degrees. ERG conjugated beads were washed twice
with 700 μl binding buffer to remove unbound protein and then blocked with BSA in NP-40
lysis buffer (50mM Tris-HCl pH 7.4, 250mM NaCl, 5mM EDTA, 10mM NaF, and 1% Nonidet
P-40). 14 μg of PC3 nuclear extract (Santa Cruz Biotechnology) was added and incubated for 2
hrs at 4 degrees. Samples were washed twice with 700 μl NP-40 lysis buffer to remove unbound
protein. Compounds were then added at designated concentrations and incubated for 1 hr at 4
degrees. After washing four times with NP-40 lysis buffer, proteins were eluted in SDS loading
dye, separated using SDS-PAGE gels, and transferred to nitrocellulose membranes. ERG was
visualized using Ponceau staining (0.1% in 5% acetic acid) and an interaction with EWS was
measured by immunoblot. Purified EWS input was measured by standard coomassie quick
staining of SDS-PAGE gels.
Cell culture and antibodies
RWPE1 and VCaP cells were obtained from ATCC and grown according to ATCC guidelines
as follows: RWPE1 and RWPE1-ERG cells were grown in Keratinocyte SFM (ThermoFisher)
and VCaP cells in Dulbecco’s modification Eagle media (Sigma) with 10% fetal bovine serum
(Sigma). RWPE1-ERG cells were created using retroviral transduction with ERG expressed
under control of the HNRNPA2B1 promoter as previously reported [9]. Both RWPE1 and
VCaP lines were authenticated by the University of Arizona Genetics Core using Powerplex
16HS Assay (Promega). All cell lines used have tested negative for mycoplasma using the
Mycoplasma Detection Kit (Sigma). The EWS antibody (sc-28327, lot number: B0315) is a
mouse monoclonal from Santa Cruz Biotechnology. Immunoblot using the EWS antibody was
performed at 1:1000. The FLAG antibody a mouse monoclonal from Sigma (F1804, lot num-
ber: SLBQ6349V). Immunoblot using the FLAG antibody was performed at 1:1000.
Migration assay, clonogenic growth assay, and cell viability assay
Migration assays using RWPE1-ERG cells were performed as previously described [8]. Briefly,
50,000 cells were seeded into the transwell insert (8-micron pore size, BD bioscience). Either
DMSO or each compound at the indicated concentration was added to the insert and cells
were incubated at 37 C with 5% CO2 for 72hrs. Inserts were then removed, stained, mounted,
imaged and quantified. Migrated cells are reported as the mean of three biological replicates,
each with two technical replicates. Clonogenic growth assays were performed as previously
described [9]. 1,000 RWPE1-ERG cells were seeded in each well of a 6 well plate. Cells were
incubated for 3 days at 37 degrees Celsius with 5% CO2 prior to the addition of DMSO or
45 μM of each compound. Cells were then incubated for an additional 7 days at 37 C with 5%
CO2 before they were fixed with 10% formalin and stained with 0.5% crystal violet in 25%
methanol. Stained colonies were imaged and counted using Genesys image acquisition and
analysis software (Syngene). Number of colonies are reported as the mean of three biological
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replicates, each with two technical replicates. To measure cell viability, 1,500 RWPE1-ERG
cells were seeded per well in a 96 well plate. After incubating the cells for 1 day at 37 C with 5%
CO2, DMSO or 45 μM of compound was added. Cells were then incubated for an additional 4
days after which MTT reagent (5mg/ml in PBS) was added. After incubation for 4hrs, media
was removed and DMSO was added. Absorbance was measured using the ELx8200 plate
reader (BioTek Instruments). Cell viability is reported as the mean of three biological repli-
cates, each with four technical replicates.
Luciferase assays
Luciferase assays were performed as previously described [9]. We used the firefly luciferase
reporter pGL4.25 (Promega) driven by the ETS-motif containing FLH3 enhancer as expression
of this reporter has been previously shown to require ERG-EWS [9]. Dual luciferase reportor
assay kit (Promega) was used to measure luciferase activity. Relative luciferase activity is
reported as the mean of three biological replicates, after normalizing firefly values to renilla
values. All biological replicates contain two technical replicates.
RNA extraction and quantitative reverse transcription PCR
RNA was extracted using the RNAeasy kit (Qiagen). 1 μg of RNA was reverse transcribed
using the following 3’ primers: 5’-CATGTTGGGTTTGCTCTTCC-3’ for ERG, 5’- TCAGA
ACCATAGAAGACACC-3’ for HSPA8, and 5’-GACTTTGGTTTCCCGGAAGC-3’ for 18S.
RNA was measured using standard curves as previously described [12] using the 3’ reverse
transcription primers and the following 5’ primers: 5’-ACCATCTCCTTCCACAGTGC-3’ for
ERG, 5’-CCAACACAGTTTTTGATGCC-3’ for HSPA8, and 5’-GGTGAAATTCTTGGACC
GGC-3’ for 18S. Expression of ERG is normalized to 18S and reported as three biological rep-
licates each represented by the average of two technical replicates.
Statistical analysis
We performed unpaired t-tests to compare the difference between the DMSO control group
and individual Hit treated groups in phenotypic and qRTPCR assays. P values reported above




We chose to implement the AlphaScreen technology to find small molecule inhibitors of the
ERG-EWS protein-protein interaction. AlphaScreens have been used to identify protein-pro-
tein interaction inhibitors and are a robust and sensitive method [13, 14]. A pipeline for screen
preparation, performance, validation and hit-to-lead generation is detailed in Fig 1.
EWS 1-355aa interacts with ERG
The sensitivity of HTS requires clean protein preparations to limit assay interference. EWS is
difficult to purify in full length because it is prone to aggregation and is rapidly degraded [15,
16]. We therefore sought to identify a more stable fragment of EWS capable of interacting with
ERG that could be purified without the presence of degradation products. N-terminal Flag-
GST-tagged versions of full-length EWS, or C-terminal or N-terminal regions of EWS were
purified and assayed for interaction with His-tagged ERG. The N-terminal fragment, EWS 1-
355aa, was able to interact with ERG, better than full length EWS 1-656aa, while the C-
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terminal fragment, EWS 459-656aa was unable to interact (Fig 2A). Interestingly, an N-termi-
nal degradation product arising from full-length EWS, and about the same size as EWS 1–355,
also interacted with ERG better than full-length EWS. Based on these findings, we decided to
use EWS 1-355aa for HTS.
To determine the concentration of protein to use in the screen, a cross titration was per-
formed using the AlphaScreen beads. Because the proteins were tagged with His and GST,
they were directly conjugated to the nickel chelate acceptor and glutathione donor beads,
respectively. The concentration of each purified protein was varied while the beads were kept
at a constant final concentration of 0.4 μg per well. A matrix of 100, 30, 10, 3, or 0 nM of ERG
with 100, 30, 10, 3, or 0 nM of EWS 1-355aa was used to determine optimal signal intensity
output. Use of 30 nM of each protein resulted in strong assay signal and was selected for the
screen. Lesser concentrations of either protein caused a robust decrease in signal intensity (Fig
2B).
Fig 1. Pipeline for identifying small molecule inhibitors of ERG-EWS using HTS.
https://doi.org/10.1371/journal.pone.0238999.g001
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Fig 2. EWS 1-355aa interacts with ERG. A) His-tag affinity pull down of purified EWS fragments. Purified His-ERG
was conjugated to cobalt beads and used to pull down indicated FLAG-GST-EWS proteins. An interaction with EWS
is indicated by the FLAG immunoblot. EWS input is shown as a coomassie stained SDS-PAGE gel. B) Surface plot of
cross-titration of ERG and EWS 1-355aa. Concentration of proteins are indicated. Signal intensity is an arbitrary
measurement of fluorescence.
https://doi.org/10.1371/journal.pone.0238999.g002
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AlphaScreen quality control
Before performing HTS, we determined the AlphaScreen signal separation between positive
and negative controls. This is important in determining the ability of the assay reagents or the
purified protein to interfere with the instrumentation. 70 replicates of the AlphaScreen were
performed using the both proteins conjugated to their corresponding beads (positive control)
and the following negative controls: unconjugated beads, ERG conjugated to acceptor beads in
the presence of unconjugated donor beads, and EWS 1-355aa conjugated to donor beads in
the presence of unconjugated acceptor beads (Fig 3A–3C). The z’ robust, an outlier-indepen-
dent measure of interference that takes into consideration the means and standard deviations
of both the positive and negative controls [11, 17], was calculated. A Z’ value greater than 0.5
indicates an excellent assay set up [11]. The Z’ robust value for no protein was 0.825, for ERG
only, 0.846, and for EWS 1-355aa only, 0.725 (Fig 3D), indicating the assay setup allowed mini-
mal interference with the instrumentation.
AlphaScreen hit generation and validation
We used three small molecule libraries—Lopac 1280, Microsource Spectrum 2400, and Analy-
ticon Natx 5000—for a total of 8680 compounds. Each 384 well assay plate was stamped with
compounds from the mother library plates in columns 3–22 to give each compound a concen-
tration of 62.5 μM. Columns 1 and 24 contained assay buffer only. Column 2 contained
Fig 3. Z’ Robust determination. A-C) Z’ determination of the AlphaScreen system using beads alone without protein compared to both proteins (A), ERG conjugated to
beads compared to both proteins with beads (B), and EWS 1-355aa conjugated to beads compared to both proteins with beads (C). D) Z’ robust values for corresponding
conditions.
https://doi.org/10.1371/journal.pone.0238999.g003
PLOS ONE Inhibition of the ERG/EWS interaction
PLOS ONE | https://doi.org/10.1371/journal.pone.0238999 September 11, 2020 7 / 13
purified ERG and EWS 1-355aa in assay buffer with DMSO and was used for background
measurements for each plate. Column 22 contained protein-bead conjugates in assay buffer
with DMSO and served as the positive control for each plate.The percent activity compared to
the positive control was plotted, where percent activity is the signal minus background over
the signal from the positive control multiplied by 100 (Fig 4A). Small molecules were called
“hits” if they yielded a percent activity less than 35%. Eighteen hits were validated using the
AlphaScreen in duplicate, along with two compounds that enhanced the protein-protein inter-
action (Fig 4B). From the 18 initial hits, six small molecules resulted in less than 10% percent
activity compared to the DMSO control in the duplicate assay. Four of these six validated
small molecules were commercially available, so these were chosen for hit-to-lead generation
(Fig 4C).
Hit-to-lead generation
The four hit small molecules were tested for the ability to inhibit the ERG-EWS protein-pro-
tein interaction in a secondary, fluorescent-independent assay. Importantly, we wanted to
understand if the hits would inhibit the interaction between ERG and native full-length EWS.
Purified His-ERG was bound to cobalt beads and used as bait to pull-down native EWS from
prostate cancer cell line PC3 nuclear extract. Hits A, B, C, and D were added in the same con-
centration used in HTS, 62.5 μM. Compared to the DMSO control, treatment with Hit B or
Hit D had the greatest effect (Fig 5A, upper). Several of the hit compounds are metal chelators
that could interfere with the cobalt bead chemistry. However, ponceau staining indicated that
none of the tested compounds decreased ERG binding to the beads (Fig 5A, lower). We then
tested if lower concentrations of Hit B could disrupt the interaction. Inhibition of the
ERG-EWS interaction by Hit B in two replicate experiments was dose-dependent, with slightly
reduced inhibition at 45 μM and very little inhibition at 30 μM (Fig 5B).
We next wanted to test the ability of Hit B to inhibit known ERG-EWS-mediated cancer-
associated phenotypes. We have previously shown that ectopic expression of ERG in an
immortalized-normal prostate cell line (RWPE1) can drive cell migration, clonogenic survival,
and target gene activation dependent on the interaction with EWS [9]. Importantly, the intro-
duction of ERG does not alter RWPE1 viability or 2-D cell proliferation [9]. Interestingly,
despite the high concentration, 45 μM Hit B had little effect on RWPE-ERG cell viability (Fig
5C). In contrast, 45 μM Hit B dramatically decreased the ERG-mediated phenotypes of cell
migration (Fig 5D) and clonogenic growth (Fig 5E). In the case of cell migration, another com-
pound, Hit D, had little effect at 45 μM, indicating that inhibition is a unique feature of Hit B.
Two assays were used to determine the half maximal inhibitory concentration (IC50) of Hit
B on ERG function in RWPE1 cells. First cell migration (Fig 5F), and second a reporter assay
(Fig 5G) where luciferase expression was driven by a known ERG cis-regulatory element, pre-
viously shown to require EWS co-activator function [9]. RWPE1-ERG cells were treated with
a serial dilution of Hit B for each assay. The IC50 for Hit B was ~9 μM in both assays indicating
that lower concentrations of the compound might be functional in cells than in the in vitro
protein-protein interaction assay.
To test if the lead compounds alter protein stability or transactivation function, we used the
VCaP prostate cancer cell line which harbors the TMPRSS2/ERG rearrangement. The
TMPRSS2/ERG fusion in VCaP cells drives expression of an N-terminally truncated ERG pro-
tein. This truncated ERG binds the other, native ERG allele to drive expression of full length
ERG [18]. Treatment of either Hit B or Hit D (45 μM) had no impact on EWS protein level as
measured by immunoblot (Fig 5H, top panel). Treatment of Hit B, but not Hit D, reduced
expression of full length ERG (Fig 5H, middle panel, top band) but not the truncated ERG
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encoded by the TMPRSS2/ERG fusion (Fig 5H, middle panel, bottom band). These findings
are consistent with Hit B altering the transcriptional activation function of ERG in VCaP cells.
Therefore, we tested if Hit B could reduce mRNA levels of ERG target genes. Treatment of
VCaP cells with 45 μM Hit B led to significant decreases in ERG and HSPA8 mRNA
Fig 4. AlphaScreen and validation. A) Results of HTS. Percent assay activity compared to the DMSO control was plotted for the 8680 compounds tested.
Compounds that resulted in less than 35% activity were considered initial hits. B) Validation of hits. Eighteen inhibitor hits and two protein-protein
interaction enhancers were used in the AlphaScreen performed in duplicate and percent activity compared to the DMSO control was plotted. Libraries from
which compounds are from are labeled below. C) Structures and hit ID of the four commercially available validated hits.
https://doi.org/10.1371/journal.pone.0238999.g004
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Fig 5. Secondary assays determine lead compounds. A) His-tag affinity pull-down validation of hits using PC3 nuclear extract which
contains native EWS. Purified His-ERG was used as bait and ERG protein is shown by Ponceau stain (bottom). EWS signal is shown by
EWS immunoblot (top). 62.5 μM of indicated Hit compounds were used. B) His-tag affinity pull-down as in (A) except using 60, 45, and
PLOS ONE Inhibition of the ERG/EWS interaction
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expression, measured by qRTPCR. In contrast, Hit D did not alter expression of ERG or
HSPA8 (Fig 5I).
Discussion
In this study we find that AlphaScreen technology is a feasible HTS approach to identify small
molecule inhibitors of ERG-EWS. We identified six validated hits from the AlphaScreen. Four
of these compounds were available commercially, and two were able to decrease the ERG-EWS
interaction using a secondary, non-fluorescent based protein-protein interaction assay. One
hit compound, Hit B, was able to significantly inhibit the ERG-EWS mediated phenotypes cell
migration, clonogenic growth, and reporter expression. Hit B was also able to decrease ERG
target gene expression and expression of full length ERG protein. The concentrations neces-
sary for inhibition were relatively high, however, these findings validate the usefulness of this
screening technique to identify higher affinity compounds and indicate that Hit B could pro-
vide a lead compound for these efforts.
Hit B is 1,10-phenanthroline which has been previously studied as a possible cytotoxic ther-
apeutic in liver and kidney cancer cell lines [19]. Our screen identified 1,10-phenanthroline as
a compound that could disrupt the ERG/EWS protein-protein interaction that we have previ-
ously shown is necessary for ERG transactivation function. The immunoblot in Fig 5H sup-
ports a transcriptional inhibitory role, as 1,10 phenanthroline preferentially decreases full-
length ERG compared to the truncated ERG encoded by TMRPSS2/ERG. ERG protein is
involved in a positive feedback loop with the native ERG locus: both full length and truncated
ERG bind the ERG promoter to active ERG transcription [18]. However, TMPRSS2/ERG is not
ERG regulated since the native promoter is lost. To further support this result, ERG expression
at the RNA level is significantly decreased by 1,10 phenantholine treatment, as well as another
ERG downstream target, HSPA8 (Fig 5I). However, these data do not rule out the possibility
that 1,10 phenanthroline specifically alters full length ERG protein stability while not affecting
truncated ERG. One limitation of this study is that engineered ERG was used to pull down
EWS from cell extracts. Further testing is needed to verify that 1,10 phenanthroline can in fact
inhibit the endogenous protein-protein interaction in cells, as well as in vivo.
IDRs often oscillate dynamically between structures. This is modulated by post-transla-
tional modifications and interactions with various macromolecules [2, 20]. Both the interact-
ing interfaces of ERG and EWS are predicted to be intrinsically disordered, posing a challenge
for the development of small molecule inhibitors based on structure alone. Therefore, many
diverse small molecules must be systematically tested for the ability to interfere with this type
of unstructured interface. It is possible to target IDRs with small molecules. Biotinylated isoxa-
zole, or b-isox, is a small molecule that binds to IDRs in RNA binding proteins, including the
N-terminus of EWS, that are associated with RNA granules [21]. B-isox binding disrupts gran-
ule formation by trapping the IDR in a structured state, suggesting that small molecule binding
30 μM of Hit B. Two independent experiments are shown (EXP1, top; EXP2, bottom). C) Cell viability assay using RWPE1-ERG cells
after treatment with 45 μM of indicated compound or DMSO. D) Cell migration assay using RWPE1-ERG cells after treatment with
45 μM of indicated compound or DMSO. E) Clonogenic growth assay using RWPE1-ERG cells after treatment with 45 μM of indicated
compound or DMSO. F) IC50 determination by migration assay using RWPE1-ERG cells after treatment with DMSO or indicated
compound concentrations in μM. The IC50, indicated by the point in which the red dashed line crosses the cell migration curve, is
estimated to be ~9 μM. G) IC50 determination by luciferase assay. Luciferase expression is driven by an ETS-motif-containing enhancer
element and firefly expression is normalized to renilla expression. IC50, indicated by the point in which the red dashed line crosses the
relative luciferase curve, is estimated to be ~9 μM. H) Immunoblot of ERG and EWS from VCaP cells after treatment with 45 μM of
indicated compound or DMSO for 24 hr. Tubulin (TUB) is used as a loading control. I) qRTPCR of known ERG target genes after
treatment with 45 μM of indicated compound or DMSO for 24 hr in VCaP cells.
https://doi.org/10.1371/journal.pone.0238999.g005
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to its target inhibits target function [21]. While B-isox lacks target specificity, it proves that
IDRs can be targeted by small molecules.
This study is the first to screen for small molecule inhibitors of ERG-EWS. We screened
8680 molecules and found one candidate lead inhibitor, 1,10-phenanthroline. While 1,10-phe-
nanthroline inhibited ERG-EWS at a high concentration, the AlphaScreen setup described
here provides the basis and rationale for expansion of this screen using larger chemical librar-
ies or derivative libraries synthesized from the lead compound identified in this study.
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